A stage D2 prostate cancer patient with biopsy-proven lung metastases and negative work-up for metastases is discussed. Treatment consisted of hormonal therapy in the form of chronic administration of an analog of gonadotropin-releasing hormone (GnRH-A), Buserelin, with follow-up for 24 months. The complete response of the patient to GnRH-A therapy provides an interesting and unusual case in the understanding of the biological behavior of prostate cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pros.2990100105 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!